RESUMO
Epilepsy modeling is essential for understanding the basic mechanisms of the epileptic process. The Genetic Audiogenic Seizure Hamster (GASH:Sal) exhibits generalized tonic-clonic seizures of genetic origin in response to sound stimulation and is currently being validated as a reliable model of epilepsy. Here, we performed a pharmacological and neuroethological study using well-known and widely used antiepileptic drugs (AEDs), including phenobarbital (PB), valproic acid (VPA), and levetiracetam (LEV). The intraperitoneal administration of PB (5-20mg/kg) and VPA (100-300mg/kg) produced a dose-dependent decrease in GASH:Sal audiogenic seizure severity scores. The administration of LEV (30-100mg/kg) did not produce a clear effect. Phenobarbital showed a short plasmatic life and had a high antiepileptic effect starting at 10mg/kg that was accompanied by ataxia. Valproic acid acted only at high concentrations and was the AED with the most ataxic effects. Levetiracetam at all doses also produced sedation and ataxia side effects. We conclude that the GASH:Sal is a reliable genetic model of epilepsy suitable to evaluate AEDs.
Assuntos
Anticonvulsivantes/uso terapêutico , Comportamento Animal/efeitos dos fármacos , Epilepsia Reflexa/complicações , Epilepsia Reflexa/tratamento farmacológico , Estimulação Acústica/efeitos adversos , Animais , Anticonvulsivantes/sangue , Anticonvulsivantes/farmacologia , Cromatografia Líquida de Alta Pressão , Cricetinae , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Epilepsia Reflexa/genética , Proteínas de Homeodomínio/genética , Levetiracetam , Locomoção/efeitos dos fármacos , Masculino , Espectrometria de Massas , Fenobarbital/sangue , Fenobarbital/farmacologia , Fenobarbital/uso terapêutico , Piracetam/análogos & derivados , Piracetam/sangue , Piracetam/farmacologia , Piracetam/uso terapêutico , Fatores de Tempo , Fatores de Transcrição/genética , Ácido Valproico/sangue , Ácido Valproico/farmacologia , Ácido Valproico/uso terapêuticoRESUMO
A high-performance liquid chromatography (HPLC) assay using UV detection is described for the simultaneous measurement of the newer generation anti-epileptic medications lamotrigine, oxcarbazepine (parent drug and active metabolite 10- hydroxycarbazepine), and zonisamide. Detection of all four compounds can be done at 230 nm; however, there is a potential interference with zonisamide in patients on clonazepam therapy. Therefore, the method uses dual wavelength detection: 230 nm for oxcarbazepine and 10-hydroxycarbazepine and 270 nm for lamotrigine and zonisamide. In addition, a simple gas chromatography method using a nitrogen-phosphorus detector is described for the measurement of levetiracetam, another of the recently approved anti-epileptic medications. For both methods, limits of quantitation, linearities, accuracies, and imprecisions cover the therapeutic range for drug monitoring of patients. A wide variety of clinical drugs, including other anti-epileptic drugs, do not interfere with these assays. These procedures would be of special interest to clinical laboratories, particularly due to the limited availability of immunoassays for newer generation anti-epileptic medications and that therapeutic uses of these drugs are expanding beyond epilepsy to other neurologic and psychiatric disorders.
Assuntos
Anticonvulsivantes/sangue , Carbamazepina/análogos & derivados , Cromatografia Gasosa/métodos , Cromatografia Líquida de Alta Pressão/métodos , Isoxazóis/sangue , Piracetam/análogos & derivados , Triazinas/sangue , Carbamazepina/análise , Carbamazepina/sangue , Humanos , Lamotrigina , Levetiracetam , Nitrogênio/análise , Oxcarbazepina , Fósforo/análise , Piracetam/sangue , Reprodutibilidade dos Testes , Raios Ultravioleta , ZonisamidaRESUMO
Using a rat model which allows serial blood sampling and concurrent brain microdialysis sampling, we have investigated the temporal kinetic inter-relationship of levetiracetam in serum and brain extracellular fluid (frontal cortex and hippocampus) following systemic administration of levetiracetam, a new antiepileptic drug. Concurrent extracellular amino acid concentrations were also determined. After administration (40 or 80 mg kg(-1)), levetiracetam rapidly appeared in both serum (T(max), 0.4 - 0.7 h) and extracellular fluid (T(max), 2.0 - 2.5 h) and concentrations rose linearly and dose-dependently, suggesting that transport across the blood-brain barrier is rapid and not rate-limiting. The serum free fraction (free/total serum concentration ratio; mean+/-s.e.mean range 0.93 - 1.05) was independent of concentration and confirms that levetiracetam is not bound to blood proteins. The kinetic profiles for the hippocampus and frontal cortex were indistinguishable suggesting that levetiracetam distribution in the brain is not brain region specific. However, t(1/2) values were significantly larger than those for serum (mean range, 3.0 - 3.3 h vs 2.1 - 2.3 h) and concentrations did not attain equilibrium with respect to serum. Levetiracetam (80 mg kg(-1)) was associated with a significant reduction in taurine in the hippocampus and frontal cortex. Other amino acids were unaffected by levetiracetam. Levetiracetam readily and rapidly enters the brain without regional specificity. Its prolonged efflux from and slow equilibration within the brain may explain, in part, its long duration of action. The concurrent changes in taurine may contribute to its mechanism of action.